NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

Sabina ChiarettiDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Marilisa MarinelliDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Ilaria Del GiudiceDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Silvia BoninaDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Alfonso PiciocchiGIMEMA Data Center, GIMEMA Foundation, Rome, Italy

Monica MessinaDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Marco VignettiDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy;GIMEMA Data Center, GIMEMA Foundation, Rome, Italy

Davide RossiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Valeria Di MaioDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Francesca Romana MauroDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Anna GuariniDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy

Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Robin FoàDivision of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, ItalyCorrespondence[email protected] [email protected]

show all

NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date